biostudies-literatureBersini SNCI NIH HHS36110-36125https://www.ebi.ac.uk/biostudies/studies/S-EPMC6281425biostudies-literatureUnknown9(90)The reciprocal interaction between circulating tumor cells (CTCs) and tissue-specific cells is influential for the progression of metastases. In particular, the process of extravasation relies on the complex cross-talk between cancer cells and other cellular players such as the endothelium and the secondary tissue. However, most <i>in vitro</i> studies only focus on one heterotypic cell-cell interaction and often lack of physiological relevance. In this project, we investigated both CTC-endothelium and CTC-secondary site interactions during cancer cell extravasation. We first used a microarray analysis of extravasated MDA-MB-231 breast cancer cells to identify key markers involved in extravasation. Then, we developed a tri-culture microfluidic platform combining cancer cells, endothelium aOncotargetA combined microfluidic-transcriptomic approach to characterize the extravasation potential of cancer cells.PMC6281425U01 CA202177Moretti MMiermont AKamm RDBersini SAdriani GThiery JPPavesi AfalseA combined microfluidic-transcriptomic approach to characterize the extravasation potential of cancer cells.The reciprocal interaction between circulating tumor cells (CTCs) and tissue-specific cells is influential for the progression of metastases. In particular, the process of extravasation relies on the complex cross-talk between cancer cells and other cellular players such as the endothelium and the secondary tissue. However, most <i>in vitro</i> studies only focus on one heterotypic cell-cell interaction and often lack of physiological relevance. In this project, we investigated both CTC-endothelium and CTC-secondary site interactions during cancer cell extravasation. We first used a microarray analysis of extravasated MDA-MB-231 breast cancer cells to identify key markers involved in extravasation. Then, we developed a tri-culture microfluidic platform combining cancer cells, endothelium a2018-01-01T00:00:00Z2018 Nov2026-05-06T06:27:42.492Z2019-10-30T08:14:29ZS-EPMC62814253054683110.18632/oncotarget.26306